These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32376036)

  • 1. Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia.
    Lee SJ; Oh J; Hong SJ; Cho IJ; Kim SR; Uhm JS; Shim CY; Chang HJ; Ahn CM; Kim JS; Kim BK; Park S; Lee SH; Hong GR; Ko YG; Choi D
    Clin Ther; 2020 Jun; 42(6):1058-1066.e3. PubMed ID: 32376036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
    Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
    BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
    Hong SJ; Jeong HS; Cho JM; Chang K; Pyun WB; Ahn Y; Hyon MS; Kang WC; Lee JH; Kim HS
    Clin Ther; 2019 Feb; 41(2):233-248.e9. PubMed ID: 30665829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
    Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
    Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study.
    Oh GC; Han JK; Han KH; Hyon MS; Doh JH; Kim MH; Jeong JO; Bae JH; Kim SH; Yoo BS; Baek SH; Rhee MY; Ihm SH; Sung JH; Choi YJ; Kim SJ; Hong KS; Lee BK; Cho J; Shin ES; Rhew JY; Kim H; Kim HS
    Clin Ther; 2018 May; 40(5):676-691.e1. PubMed ID: 29673890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
    Lee J; Rhee SJ; Lee S; Yu KS
    Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study.
    Kim TS; Rha SW; Kim SY; Park DG; Sung KC; Yoon MH; Kim KH; Lee HC; Kim WS; Kim YJ; Ahn JC; Rhee MY; Cha DH; Yoo BS; Park SH; Yoo KD; Jeon DW; Yoon YW; Cho SK; Oh YS
    Clin Ther; 2019 Apr; 41(4):728-741. PubMed ID: 30904178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
    Galeeva ZM; Galiavich AS
    Ter Arkh; 2014; 86(9):71-6. PubMed ID: 25518509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
    Oh M; Ghim JL; Park SE; Kim EY; Shin JG
    Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
    Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
    Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
    Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
    Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
    Jin X; Kim MH; Han KH; Hong SJ; Ahn JC; Sung JH; Cho JM; Lee HC; Choi SY; Lee K; Kim WS; Rhee MY; Kim JH; Hong SP; Yoo BS; Cho EJ; Lee JH; Kim PJ; Park CG; Hyon MS; Shin JH; Lee SH; Sung KC; Hwang J; Kwon K; Chae IH; Seo JS; Kim H; Lee H; Cho Y; Kim HS
    J Clin Hypertens (Greenwich); 2020 Oct; 22(10):1835-1845. PubMed ID: 32937023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study.
    Cho KI; Kim BH; Park YH; Ahn JC; Kim SH; Chung WJ; Kim W; Sohn IS; Shin JH; Kim YJ; Chang K; Yu CW; Ahn SH; Kim SY; Ryu JK; Lee JY; Hong BK; Hong TJ; Gyu Park C
    Clin Ther; 2019 Aug; 41(8):1508-1521. PubMed ID: 31307833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
    Lee HY; Kim CH; Song JK; Chae SC; Jeong MH; Kim DS; Oh BH
    Korean J Intern Med; 2017 Nov; 32(6):1025-1036. PubMed ID: 29032666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.